Therapeutic efficacy of imatinibmesilate (glivek) in chronic phase of myeloid leukemia


Cite item

Full Text

Abstract

Aim. To evaluate efficacy and tolerance ofglivek in chronic myeloid leukemia (CML) in patients who
failed interferon-alpha (If-a) preparations.
Material and methods. 79 patients in a chronic phase of Ph+CML with hematological and cytogenetic
resistance or intolerance of If-a. The response to glivec was assessed by achievement of a complete
hematological remission and the cytogenetic effect (the degree of reduction of cell clone Ph+ in bone
marrow). Tolerance and safety of the drug was studied by monthly standard clinicohematological tests.
Results. Not only a hematological remission (92.4%), but also partial (46.8%) or complete (27.8%)
elimination of BCR-ABL±cells were achieved after 12 months of the treatment. Glivec was well tolerated.
Hematological toxicity primarily as neutropenia and thrombocytopenia were observed in 54.4
and 42% patients, respectively. Neutropenia of the third degree which made impossible to continue the
treatment was observed in 29.1% patients; throbocytopenia of the third degree was registered in 16.5%
patients. Among most frequent поп-hematological side effects there were moderate edema, nausea, leg
muscle convulsions, weight gain, arthralgias, skin eruption. All the complications were transient, were
managed in all cases with only a short-time discontinuation of glivec therapy.
Conclusion. High activity of glivec at early stages of CML allows using this drug as a first-line therapy
in patients with CML

References

  1. Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia giemsa starting. Nature 1973; 243: 290-303.
  2. Gordon M. Y. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment. Br. J. Haematol. 1996; 95: 10-20.
  3. Druker B. J., Lydon N. B. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myeloid leukemia. J. Clin. Invest. 2000; 105: 3-7.
  4. Deininger M. V., Goldman G. J., Lydon N., Melo J. V. The tyrosine kinase inhibitor CGP571148 В selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90: 3691- 3698.
  5. Kantarjian H. M., O'Brien S., Anderini P., Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigation options. J. Am. Soc. Hematol. 1996; 87 (8): 3069- 3080.
  6. Allan N. C., Richards S. M., Sheperd P. С. A et al. UK Medical Research Council randomised multicentre trial of interferon-cc in chronic myeloid leukaemia: improved servival irrespective of cytogenetic response. Lancet 1995; 345: 1392- 1397.
  7. Kantarjian H. M., Francis J., O'Brien S., Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and hemotherapy. Hematol./Oncol. Clin. N. Am. 1998; 12 (1): 31-79.
  8. Druker B. J., Talpaz M., Debra J. et al. Efficacy and safety of specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. 2001; 344 (14): 1031 - 1037.
  9. Kantarjian H., Sawyers C. L., Hochhaus A. et al. Phase 11 study of STI571 in patients with resistance or refractory Philadelphia chromosome positive chronic myeloid leukemia. Blood 2000; 96: 470a.
  10. Talpaz M., Kautarjian H. M., McCredie К. В. et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N. Engl. J. Med. 1986; 314: 1065-1069.
  11. Юнис Дж. Дж. В кн. Современная гематология и онкология. М.: Медицина; 1987. 351-390.
  12. Pinkel D., Straume Т., Gray У. W., Proc. Natl. Acad. Sci., USA 1986; 2934-2938.
  13. Kobzev Y. N., Domracheva E. V., Zakharova A. V. et al. Cancer Genet. Cytogenet. 1998; 106: 128-134.
  14. Kantarjian H. M., Smith T. L., McCredie К. В. et al. Chronic myelogenous leukemia: a multivariate analysis of the association patient characteristics and therapy with survival. Blood 1985; 66: 1326-1335.
  15. Хорошко Н. Д. Современная терапия хронического миелолейкоза: Автореф. дис. ... д-ра мед. наук. М.; 1992.
  16. Туркина А. Г. Клиническое значение молекулярно-генетических и иммунофенотипических характеристик хронического миелолейкоза: Автореф. дис. д-ра мед. наук. М.; 1998.
  17. Хорошко Н. Д., Туркина А. Г., Кузнецов С. В. и др. Хронический миелолейкоз - успехи современного лечения и перспективы. Гематол. и трансфузиол. 2001; 4: 7-12.
  18. Talpaz V., Silver R. Т., Druker В. J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99 (6): 1928-1937.
  19. Kantarjian H. M., O'Brien S., Cortes J. Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesilate (STI571). In: Hematology. Orlando, Florida; 2001; abstr. 594.
  20. Druker B. J., Charles L., Saviers С L. Activity of specific inhibitor of BCR-ABL tyrosin kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001; 344: 1038-1042.
  21. Михайлова И. Н. Клинико-иммунофенотипическая характеристика бластного кризахронического миелолейкоза: Автореф. дис. ... канд. мед. наук. М.; 1995.
  22. Larson R. On behaf of IRIS Imatinib (STI571 Glivec) as initial therapy for patients with newly Ph+ chronic myelod leukemia (CML): results of a randomized phase III study vs interferon +Ara-C in). Blood 2002; 100 (11): 48

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies